Olanzapine to Prevent Weight and Appetite Loss in Cancer Patients Before Surgery
Tests olanzapine against appetite and weight loss in people having chemotherapy before surgery.
Plain-language title generated from the registry record
Registry title: Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy
Key facts
- Where
- Moscow, RussiaSee the site
- Phase
- Phase 3
Where in Russia
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian FederationMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Blokhin's Russian Cancer Research Center
- Trial code
- NCT07633236
- Record updated
- 8 June 2026
- Original description
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:Read full original descriptionShow less
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients With Localized and Locally Advanced Tumors Receiving Neoadjuvant/Preoperative Chemotherapy
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:
Is prolonged low-dose olanzapine effective and save in:
* Preventing/treating weight loss due to anorexia. * Controlling nausea/vomiting. * Maintaining anticancer therapy dose intensity?
Does prolonged low-dose olanzapine improve quality of life in patients receiving neoadjuvant/preoperative chemotherapy?
Participants will:
Take prolonged low-dose olanzapine (2.5 mg/day) in treatment group or usual diet only in control group until surgical treatment Physical examination, anthropometric assessment, blood tests, quality of life, appetite and nutritional status assessment, abdominal CT, handgrip dynamometry before chemotherapy and after preoperative chemotherapy before surgery Physical examination, adverse events every visit Surgical complications within 30 days after surgery
Inclusion: Age ≥18 years; ECOG status 0-2; Localized/locally advanced ovarian or gastric cancer requiring neoadjuvant/preoperative chemotherapy followed by surgery; Ability to consume food/medications orally.
Exclusion: Systemic corticosteroid use (>7 days within the last 4 weeks); History of psychiatric disorders; Olanzapine use (>4 days) for other indications at enrollment; Current use of antipsychotics/antidepressants.